Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.…
Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California
Jyong Biotech (NASDAQ: MENS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 27 employees.
The shares were at 1.450 USD on 20 November 2026, down 95.0% over 52 weeks. Its 52-week range is 1.430 USD to 38.88 USD: the price is 96.3% below the high and 1.4% above the low.
Its market capitalisation is 110.24M USD.
Jyong Biotech reports return on equity of 18.8% and an operating margin of 0.0%.
Its debt exceeds its cash by 17.37M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 25 November 2026.